Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GSK2324
Cat. No.:
OB0425LY-042
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
GSK2324 is an active FXR agonist with anti-obesity effects.
Synonyms:
1020567-30-9; GSK-2324; 6-(4-((3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)quinoline-2-carboxylic acid; 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid
CAS No.:
1020567-30-9
Compound CID:
24771983
Formula:
C29H22Cl2N2O4
Formula Weight:
533.4
Specification
Target:
FXR
Pathway:
Metabolic enzyme/Protease
Storage:
Storage at -20°C.
Applications:
GSK2324 has been primarily explored for the treatment of diseases associated with immune system and metabolic disorders, such as diabetes and inflammatory diseases.
